Sørensen A M, Christensen M B
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark and Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Drugs Today (Barc). 2018 Sep;54(9):547-559. doi: 10.1358/dot.2018.54.9.2872500.
Type 2 diabetes mellitus is a common and severe chronic metabolic disease, which confers increased risk of cardiovascular disease and mortality. During the last decade a large number of new drugs within the classes dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP-4Is), glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT-2) inhibitors (SGLT-2Is) have been developed and tested in nine large-scale cardiovascular outcome trials (CVOTs). Here we review the evidence behind antihyperglycemic treatment of patients with type 2 diabetes with a particular focus on compiling and summarizing the evidence of hard clinical endpoints stemming from these large CVOTs.
2型糖尿病是一种常见且严重的慢性代谢性疾病，会增加心血管疾病风险和死亡率。在过去十年中，已研发出大量新型药物，包括二肽基肽酶4（DPP-4）抑制剂（DPP-4Is）、胰高血糖素样肽1（GLP-1）受体激动剂（GLP-1RAs）和钠/葡萄糖协同转运蛋白2（SGLT-2）抑制剂（SGLT-2Is），并在9项大型心血管结局试验（CVOTs）中进行了测试。在此，我们回顾2型糖尿病患者降糖治疗背后的证据，特别关注汇总和总结这些大型CVOTs得出的硬临床终点证据。
